Hormone replacement therapy (HRT) is approved by the U.S. Food and Drug Administration (FDA) for bothersome hot flashes and night sweats, vaginal dryness and discomfort, and the prevention of osteoporosis. If you brought hormone therapy up with your healthcare provider and were told no, you may have left the appointment discouraged.

Healthcare providers’ objections are usually for specific reasons. They are not always a blanket “no.” Here’s what drives those decisions, what to ask, and what else can help.

Why Your Healthcare Provider May Not Recommend HRT

Hormone therapy is meant to be individualized — weighed against your symptoms, health history, and goals. Two factors shape the answer most:

• Timing — For healthy people younger than 60 or within 10 years of menopause onset with no contraindications, the benefit-risk balance is generally favorable. The Office on Women’s Health puts the window at up to about age 59.
• Contraindications — Contraindications are medical reasons that systemic hormone therapy would be unsafe for you. They include breast cancer or another estrogen-sensitive cancer, venous thromboembolism (VTE), stroke, coronary artery disease, active liver disease, uncontrolled hypertension, and unexplained vaginal bleeding.

🗳️ If you’re not sure you agree with your healthcare provider’s recommendation about hormone therapy, what do you usually do first?

Ask more questions during the visit

Think it over and follow up later (message/call)

Get a second opinion

It depends/Something else

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook Continue with Google

Continue with Email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a member? Log In

History of Estrogen-Sensitive Cancer

Systemic therapy is generally avoided after breast cancer and other estrogen-sensitive cancers. In the past, people who had breast cancer were advised to avoid hormone therapy. But it isn’t automatic. Eligibility depends on cancer type, stage, treatment history, and symptom severity, as well as the type and dose of hormone therapy being considered.

If you have a personal history of breast cancer, it’s best to make the decision about hormone therapy with your oncologist and your menopause clinician because the decision is a complicated and highly individualized one.

Cancer type matters more than most people expect when making a decision about hormone therapy.

• May be considered — Epithelial ovarian, early-stage endometrial, and cervical cancer are cancer types where hormone therapy may be considered.
• Generally avoided — Hormone therapy is usually avoided for endometrioid or low-grade serous ovarian cancer, advanced endometrial cancer, and uterine sarcoma.
• Possible in select cases — Carefully selected people with surgically treated, early-stage, low-grade endometrial cancer may be able to use hormone therapy for bothersome vasomotor symptoms.

Without a cancer history, combined estrogen-progestogen therapy may increase breast cancer risk after about five years of use, and risk varies by formulation and duration rather than applying uniformly. The overall increase is small when weighed alongside other breast cancer risk factors. Using a transdermal form of estrogen (such as a patch or cream) and taking progesterone intermittently rather than daily may reduce that risk further.

Estrogen therapy used alone, such as by women who no longer have a uterus, has not been shown to increase breast cancer risk. Current guidance supports using estrogen alone for at least seven years before any change in breast cancer risk would be expected.

Vaginal estrogen cream used to treat the vaginal and vulvar symptoms of menopause does not carry an increased breast cancer risk.

History of Blood Clots, Stroke, or Heart Disease

Whether hormone therapy is safe for someone with a personal history of cardiovascular conditions depends on several factors:

• Age
• Time since menopause
• Formulation
• Route (transdermal versus oral)
• Other health conditions
• Previous hormone therapy use

Established coronary artery disease, stroke, or VTE are generally contraindications to systemic hormone therapy because the risks outweigh the benefits. Beyond that, several other factors need to be considered:

• Timing — Research indicates that therapy has favorable or neutral effects on coronary heart disease risk when started under age 60 or within 10 years of menopause, and professional guidance agrees with that same age window.
• Stroke risk — Risk of stroke depends on age and time from menopause. Earlier starters of hormone therapy don’t appear to carry the same increased risk.
• Route — Transdermal estrogen has been associated with reduced VTE risk compared with oral (pill) estrogen. Observational data suggest oral hormone therapy increases VTE risk while transdermal does not appear to, although more data is needed to confirm it.
• Family history — Family history is not an automatic disqualification. What matters is a personal history of clots or stroke or a known inherited clotting disorder such as factor V Leiden or antiphospholipid syndrome.
• Other factors — Heart disease risk depends on many factors, such as blood pressure and cholesterol, not just hormones. The Office on Women’s Health lists the factors your healthcare provider will want to discuss with you before you start hormone therapy.

Other Reasons HRT May Not Be Recommended

You should not use hormone therapy if you are or may be pregnant. Two more situations are worth naming specifically:

• Unexplained vaginal bleeding, which needs to be evaluated first
• Liver disease, such as cirrhosis

And two points that are often misunderstood:

• Gallbladder disease is listed as a risk of therapy, not a reason you can’t take it.
• There is an increased dementia risk with estrogen alone and estrogen plus progestin when started at 65 or older, which is part of why timing is an important consideration.

If you still have a uterus, estrogen is prescribed with a progestogen to protect the uterine lining and prevent endometrial cancer.

Second Opinions and Specialist Care

A second opinion is a fresh, individualized risk-benefit assessment — not a route to a different answer. Another clinician may agree with the first one, and that is useful information in itself. A few reminders when looking for a second opinion or a specialist:

• Choose someone who specializes in menopause care — Search the Menopause Society Practitioner Directory for a Menopause Society certified practitioner or ask friends and family for recommendations.
• Consider telehealth as a reasonable option — Check how billing works, whether the telehealth company takes insurance, and what their plan is for follow-up care after starting hormone therapy. Be wary of telehealth services promising a prescription before evaluating you.
• Bring your records — Be sure to take recent test results, your medication list, and any tracking you’ve done of your menopause symptoms to your appointments.

Frequently Asked Questions

Can I take hormone therapy if I have a family history of breast cancer or blood clots?

Family history alone is not an automatic disqualification. What weighs most heavily is your own personal history of clots or stroke, a known inherited clotting disorder, or a personal history of an estrogen-sensitive cancer. Bring the specifics to your clinician rather than assuming the answer.

Is vaginal estrogen the same as systemic hormone therapy?

No. Vaginal estrogen treats vaginal and vulvar symptoms locally and does not carry an increased breast cancer risk. If systemic therapy is off the table for you, ask whether vaginal-only treatment is still an option.

Does a “no” today mean no forever?

Not necessarily. Guidance calls for clinicians to reassess regularly and to monitor risks and benefits annually. Circumstances change — blood pressure gets controlled, a condition resolves, symptoms shift — so it’s fair to ask when the decision could be revisited.

Is a patch safer than a pill?

For clot risk, possibly. Transdermal estrogen has been associated with reduced VTE risk compared with oral estrogen, though this comes largely from observational data and more research is needed. It may be worth asking about, but it doesn’t eliminate risk.